139 related articles for article (PubMed ID: 1524802)
21. [Monoclonal antibodies versus epithelial antigens and carcinomas of the head and neck: critical analysis of the possible clinical applications].
Cavallo GP; Macario M; Regina S; Poggio E; Prat M; Morra B; Cortesina G
Acta Otorhinolaryngol Ital; 1987; 7(1):77-85. PubMed ID: 3618206
[No Abstract] [Full Text] [Related]
22. Monoclonal antibodies against squamous cell carcinoma of the upper aerodigestive mucous membranes.
Folz BJ; Görögh T; Lippert BM; Werner JA
Otolaryngol Head Neck Surg; 2000 Jan; 122(1):124-8. PubMed ID: 10629499
[TBL] [Abstract][Full Text] [Related]
23. An immunohistochemical analysis of a newly developed, mouse monoclonal p40 (BC28) antibody in lung, bladder, skin, breast, prostate, and head and neck cancers.
Tacha D; Bremer R; Haas T; Qi W
Arch Pathol Lab Med; 2014 Oct; 138(10):1358-64. PubMed ID: 24528495
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies (Mabs) in head and neck cancer.
Poliquin JF; Filion LG
J Otolaryngol; 1986 Oct; 15(5):289-92. PubMed ID: 3534285
[TBL] [Abstract][Full Text] [Related]
25. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
26. Numerical selection of optimal tumor imaging agents with application to engineered antibodies.
Williams LE; Wu AM; Yazaki PJ; Liu A; Raubitschek AA; Shively JE; Wong JY
Cancer Biother Radiopharm; 2001 Feb; 16(1):25-35. PubMed ID: 11279795
[TBL] [Abstract][Full Text] [Related]
27. [Localization of hepatocellular carcinoma with monoclonal antibodies].
Liu Y
Zhonghua Yi Xue Za Zhi; 1991 Jul; 71(7):362-5, 26. PubMed ID: 1659475
[TBL] [Abstract][Full Text] [Related]
28. SQM1 antibody defines a surface membrane antigen in squamous carcinoma of the head and neck.
Boeheim K; Speak JA; Frei E; Bernal SD
Int J Cancer; 1985 Aug; 36(2):137-42. PubMed ID: 3894247
[TBL] [Abstract][Full Text] [Related]
29. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
30. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal antibody (G10) to a common antigen of human squamous cell carcinoma: binding of the antibody to the H type 2 blood group determinant.
Kimmel KA; Carey TE; Judd WJ; McClatchey KD
J Natl Cancer Inst; 1986 Jan; 76(1):9-19. PubMed ID: 2416979
[TBL] [Abstract][Full Text] [Related]
32. Oncofetal antigen expression in head and neck carcinoma.
Gussack GS
Laryngoscope; 1992 Feb; 102(2):168-76. PubMed ID: 1738289
[TBL] [Abstract][Full Text] [Related]
33. Therapy and imaging of pancreatic carcinoma xenografts with radioiodine-labeled chimeric monoclonal antibody A10 and its Fab fragment.
Kamigaki T; Yamamoto M; Ohyanagi H; Ohya M; Shimazoe T; Kono A; Ohtani W; Narita Y; Ohkubo M; Saitoh Y
Jpn J Cancer Res; 1995 Dec; 86(12):1216-23. PubMed ID: 8636013
[TBL] [Abstract][Full Text] [Related]
34. Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas.
Heider KH; Sproll M; Susani S; Patzelt E; Beaumier P; Ostermann E; Ahorn H; Adolf GR
Cancer Immunol Immunother; 1996 Dec; 43(4):245-53. PubMed ID: 9003471
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical identification of squamous carcinoma of the head and neck with monoclonal antibody SQM1.
Böheim K; Schwarzfurtner H; Böheim C; Frei E; Bernal SD
Acta Otolaryngol; 1986; 102(3-4):333-40. PubMed ID: 3535370
[TBL] [Abstract][Full Text] [Related]
36. Proliferation-associated monoclonal antibodies: a useful tool for prognosis in squamous cell carcinomas of head and neck?
Lörz M; Meyer-Breiting E; Bettinger R; Desloovere C; Klima A
Acta Otorhinolaryngol Belg; 1989; 43(1):41-6. PubMed ID: 2801095
[TBL] [Abstract][Full Text] [Related]
37. Antigens associated with human squamous cell lung carcinoma defined by murine monoclonal antibodies.
Fernsten PD; Pekny KW; Reisfeld RA; Walker LE
Cancer Res; 1986 Jun; 46(6):2970-7. PubMed ID: 3009005
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a novel type of imaging probe based on a recombinant bivalent mini-antibody construct for detection of CD44v6-expressing squamous cell carcinoma.
Haylock AK; Spiegelberg D; Mortensen AC; Selvaraju RK; Nilvebrant J; Eriksson O; Tolmachev V; Nestor MV
Int J Oncol; 2016 Feb; 48(2):461-70. PubMed ID: 26676731
[TBL] [Abstract][Full Text] [Related]
39. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
Stein R; Blumenthal R; Sharkey RM; Goldenberg DM
Cancer; 1994 Feb; 73(3 Suppl):816-23. PubMed ID: 8306265
[TBL] [Abstract][Full Text] [Related]
40. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C
Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
